The link was further supported by the observation that biologic therapies targeting proinflammatory cytokines, interleukin (IL)‐1β or IL‐6, both key to mAIDs pathogenesis, are highly effective in treating AOSD.5, 6. This evidence concerns the gene IL6 and adult-onset Still disease.